Demographics and Baseline Characteristics of Children With Atopic Dermatitis Enrolled in a Randomized Phase 3 Study (TRuE-AD3)

被引：0
|
作者：
Siri, Dareen [1 ]
Lee, Lara Wine [2 ]
Gold, Linda Stein [3 ]
Armstrong, April [4 ]
Brar, Kanwaljit [5 ]
Holland, Kristen [6 ]
Shepard, Julie [7 ]
Devani, Alim [8 ]
Sturm, Daniel [9 ]
Angel, Brett [9 ]
Li, Qian [9 ]
Eichenfield, Lawrence [10 ]
机构：
[1] Midwest Allergy Sinus Asthma, Bloomington, IL USA
[2] Med Univ South Carolina, Charleston, SC USA
[3] Henry Ford Hlth Syst, Detroit, MI USA
[4] Univ Calif Los Angeles, Div Dermatol, Los Angeles, CA USA
[5] NYU Langone Hlth Ctr, Hassenfeld Childrens Hosp, New York, NY USA
[6] Med Coll Wisconsin, Milwaukee, WI USA
[7] Ohio Pediat Res Assoc, Dayton, OH USA
[8] Dermatol Res Inst, Calgary, AB, Canada
[9] Incyte Corp, Wilmington, DE USA
[10] Univ Calif San Diego, San Diego, CA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
021
引用
收藏
页码：AB8 / AB8
页数：1
相关论文
共 50 条
  • [21] Real-world treatment patterns and outcomes up to 1 year among children aged <12 years with moderate-to-severe atopic dermatitis (AD) enrolled in the PEDIatric STudy in Atopic Dermatitis (PEDISTAD) observational study
    Baselga, Eulalia
    Murashkin, Nikolay
    Sung, Myong Soon
    Lee, Lara Wine
    Liu, Chunyuan
    Bates, Lauren
    Zhang, Annie
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB200 - AB200
  • [22] Baseline demographics and disease characteristics of patients with episodic cluster headache: results from a phase 3 clinical trial
    Martinez, James M.
    Bardos, Jennifer N.
    Oakes, Tina M. Myers
    Zhou, Chunmei
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [23] BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS FROM THE PHASE 3 EMPOWER STUDY IN PATIENTS WITH EPISODIC MIGRAINE IN ASIA, MIDDLE EAST AND LATIN AMERICA
    Wang, Shuu-Jiun
    Roxas, Artemio, Jr.
    Saravia, Bibiana
    Kim, Byung-Kun
    Chowdhury, Debashish
    Riachi, Naji
    Tai, Mei-Ling Sharon
    Tanprawate, Surat
    Tai Ngoc Tran
    Jing, Zhao Yi
    Mikol, Daniel
    Pandhi, Shaloo
    Wen, Shihua
    Mondal, Subhayan
    Tenenbaum, Nadia
    Hours-Zesiger, Peggy
    CEPHALALGIA, 2020, 40 : 69 - 70
  • [24] Efficacy and Safety of Abrocitinib in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN study
    Eichenfield, Lawrence
    Flohr, Carsten
    Sidbury, Robert
    Szalai, Zsuzsanna
    Galus, Ryszard
    Yao, Zhirong
    Takahashi, Hidetoshi
    Barbarot, S. Ebastien
    Feeney, Claire
    Zhang, Fan
    DiBonaventura, Marco
    Rojo, Ricardo
    Valdez, Hernan
    Chan, Gary
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB146 - AB146
  • [25] Dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs and symptoms and quality of life (QoL) in children with severe AD: Results from the LIBERTY AD PEDS phase 3 clinical trial
    Paller, A.
    Cork, M. J.
    Marcoux, D.
    Zhang, H.
    Chuang, C.
    Zhang, A.
    Chao, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S84 - S84
  • [26] Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    de Bruin-Weller, Marjolein
    Blauvelt, Andrew
    Forman, Seth
    Bissonnette, Robert
    Reich, Kristian
    Soong, Weily
    Hussain, Iftikhar
    Foley, Peter
    Hide, Michihiro
    Bouaziz, Jean-David
    Gelfand, Joel M.
    Sher, Lawrence
    Schuttelaar, Marie L. A.
    Wang, Chen
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Davis, John D.
    Rajadhyaksha, Manoj
    Staudinger, Heribert
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 377 - 388
  • [27] Rapid and sustained improvement in itch in children aged 6 11 years with severe atopic dermatitis (AD) treated with dupilumab: Analysis from the LIBERTY AD PEDS phase 3 trial
    Paller, Amy S.
    Siegfried, Elaine C.
    Yosipovitch, Gil
    Silverberg, Jonathan I.
    Wu, Jashin J.
    Chen, Zhen
    Prescilla, Randy
    Rossi, Ana B.
    Delevry, Dimittri
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB140 - AB140
  • [28] Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis A Phase 3 Randomized Clinical Trial
    Simpson, Eric L.
    Paller, Amy S.
    Siegfried, Elaine C.
    Boguniewicz, Mark
    Sher, Lawrence
    Gooderham, Melinda J.
    Beck, Lisa A.
    Guttman-Yassky, Emma
    Pariser, David
    Blauvelt, Andrew
    Weisman, Jamie
    Lockshin, Benjamin
    Hultsch, Thomas
    Zhang, Qin
    Kamal, Mohamed A.
    Davis, John D.
    Akinlade, Bolanle
    Staudinger, Heribert
    Hamilton, Jennifer D.
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Gadkari, Abhijit
    Eckert, Laurent
    Stahl, Neil
    Yancopoulos, George D.
    Ruddy, Marcella
    Bansal, Ashish
    JAMA DERMATOLOGY, 2020, 156 (01) : 44 - 56
  • [29] BASELINE CHARACTERISTICS OF ADULTS ENROLLED IN THE ONGOING PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL TRIAL OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY (PROTECT)
    Wong, Muh
    Barratt, Jonathan
    Komers, Radko
    Mercer, Alex
    Rosenberg, Noah
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I142 - I144
  • [30] Atopic dermatitis in the first 3 months (AD3) predicts sensitization to aeroallergens, asthma & rhinoconjunctivitis in 5 year old children of the German MAS-90-study
    Bergmann, RL
    Edenharter, G
    Niggemann, B
    Bergmann, KE
    Forster, J
    Bauer, CP
    Wahn, V
    Zepp, F
    Wahn, U
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 99 (01) : 354 - 354
12345